Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Sibeprenlimab for IgA Nephropathy
Recruiting1 awardPhase 2 & 3
New York, New York
This trial is testing the safety and effectiveness of sibeprenlimab, an injectable medication, in patients with IgA Nephropathy who have been part of earlier studies. The medication likely helps manage symptoms or slow disease progression. Sibeprenlimab is being developed as a potential treatment for IgA nephropathy (IgAN).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service